245 Summer Street,
Boston , MA, 02210

Rank

Rank Universe
5 60

Summary

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes.

The process also focuses on companies that benefit significantly from scientific and technological advances in biotechnology.

Additiona More

Link

Directors

Oct 13, 2023
  • OSCAR MUNOZ
  • ROBERT A LAWRENCE
  • THOMAS A KENNEDY
  • BETTINA DOULTON
  • VICKI L FULLER
  • THOMAS P BOSTICK
  • PATRICIA L KAMPLING
  • DENNIS J DIRKS
  • DONALD F DONAHUE
  • MICHAEL E WILEY
  • SUSAN TOMASKY
  • DAVID M THOMAS
  • VIJAY ADVANI

Chief Compliance Officer

  • JASON POGORELEC

Fund Manager(s)

Price

  • $ 29.77 ( -0.45 )
    Dec 30, 2024
    Last Close
  • Net Assets
  • $1.7B
    Mar 27, 2024
  • Holding
  • 100
    Sep 25, 2024
    More

  • 52-Week High/Low
  • $38.17 - $29.77
  • Turnover
  • 43%
  • Expense Ratio
  • 0.58%

Documents

Prospectus

Annual Reports

Performance

YTD

-

3 Year

-0.1%

5 Year

0.61%

Best

22.84%

2020

Worst

-18.76%

2021

Alpha

FIJYX S&P 500

Chart +